What’s next for the weight loss drug maker

Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink the company’s obesity strategy. But while the market’s enthusiasm for the drug has meaningfully cooled, investors are shifting focus to…

Read More

Centene to offer buyouts to some employees

Sheldon Cooper | Lightrocket | Getty Images Centene said it offered buyouts to some employees on Monday, as the health insurer grapples with higher medical costs, funding cuts and membership declines. “Centene is positioning the company to lead the future of healthcare — working to deliver a simpler and better experience for our members and…

Read More

Trump FDA Commissioner Marty Makary out

Dr. Marty Makary resigned as FDA commissioner on Tuesday, ending a controversial tenure at the health agency. In a post on Truth Social, President Donald Trump said Kyle Diamantas, who previously worked as the top food official at the FDA, will step in as acting commissioner. In earlier remarks to reporters, Trump called Makary a…

Read More

Pfizer (PFE) earnings Q1 2026

Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press | Corbis News | Getty Images Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as its recently launched and acquired products showed growth. Older top-selling drugs, including its blood thinner…

Read More

Eli Lilly (LLY) earnings Q1 2026

David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026. Aaron Schwartz | Bloomberg | Getty Images Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past…

Read More